Table 1.

	All Subjects		Histological gastric GVHD				Clinical GI GVHD
			never		at least once		never		at least once
total n=	60		4		56		6		54
	median	range	median	range	median	range	median	range	median	range
Age	54	21–74	54	36–60	53	21–74	54	40–62	53	21–74
Day of GVHD onset	n/a	n/a	n/a	n/a	35	11–976	n/a	n/a	36	11–986
	n	%	n	%	n	%	n	%	n	%
Males	35	58%	4	100%	31	55%	5	83%	30	56%
Myeloablative Conditioning	46	77%	2	50%	44	79%	3	50%	43	80%
Donor:
Related	21	35%	0	0%	21	38%	1	17%	20	37%
Unrelated, HLA-Matched	22	37%	1	25%	21	38%	2	33%	20	37%
Unrelated with HLA-mismatch	17	28%	3	75%	14	25%	3	50%	14	26%
Indication for HCT:
Acute Leukemia	32	53%	2	50%	30	54%	3	50%	29	54%
Chronic Leukemia	8	13%	1	25%	7	13%	0	0%	8	15%
Lymphoma	3	5%	1	25%	2	4%	1	17%	2	4%
Myeloma	3	5%	0	0%	3	5%	1	17%	2	4%
MDS	11	18%	0	0%	11	20%	0	0%	11	20%
Myelofibrosis	1	2%	0	0%	1	2%	0	0%	1	2%
Aplastic Anemia	2	3%	0	0%	2	4%	1	17%	1	2%
Other GVHD sites:
Skin	25	42%	3	75%	22	39%	4	67%	18	33%
Liver	4	7%	0	0%	4	7%	0	0%	4	7%
GI GVHD prohylaxis:
CNI + MMF	20	33%	2	50%	18	32%	4	67%	16	30%
CNI + MTX	37	62%	1	25%	36	64%	2	33%	35	65%
CNI + MMF + Rapa	3	5%	1	25%	2	4%	0	0%	3	6%

Abbreviations: GVHD: graft versus host disease. GI: gastrointestinal. HLA: human leucocyte antigen. HCT: hematopoietic cell transplant. MDS: myelodysplastic syndrome. CNI: calcineurin inhibitor. MMF: mycophenolate mofetil. MTX: methotrexate. Rapa: rapamycin.